%20--%3e%3csvg%20version='1.1'%20id='Capa_1'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:xlink='http://www.w3.org/1999/xlink'%20x='0px'%20y='0px'%20viewBox='0%200%20114.1%2024.9'%20style='enable-background:new%200%200%20114.1%2024.9;'%20xml:space='preserve'%3e%3cstyle%20type='text/css'%3e%20.st0{fill:%23FFFFFF;}%20%3c/style%3e%3cg%3e%3cg%3e%3cg%3e%3cpath%20class='st0'%20d='M0.6,0.1c1.8,0,3.6,0.1,4.6,0.1c0.8,0,2.8-0.1,4-0.1c0.5,0,0.8,0.1,0.8,0.3S9.8,0.7,9.4,0.7%20c-0.4,0-0.3,0-0.7,0.1C7.9,0.9,7.6,1.4,7.5,2.5c-0.1,1-0.1,1.9-0.1,6.8v4.5c0,4.6,0.9,6.6,2.5,7.9c1.5,1.2,2.7,1.3,3.8,1.3%20c1.4,0,3-0.5,4.3-1.7c1.8-1.8,1.9-4.6,1.9-7.9V9.5c0-4.9,0-5.7-0.1-6.8c-0.1-1.1-0.3-1.6-1.4-1.8c-0.3-0.1-0.7-0.1-0.9-0.1%20c-0.4,0-0.6-0.1-0.6-0.3s0.2-0.3,0.7-0.3c1.7,0,3.8,0.1,3.8,0.1c0.4,0,2.4-0.1,3.8-0.1c0.5,0,0.7,0.1,0.7,0.3s-0.2,0.3-0.6,0.3%20s-0.4,0-0.8,0.1c-0.8,0.2-1.1,0.7-1.2,1.8c-0.1,1-0.1,1.9-0.1,6.8v3.4c0,3.6-0.4,7.3-3.1,9.6c-2.3,2-4.9,2.3-7,2.3%20c-1.8,0-6,0-8.4-2.2c-1.7-1.5-2.9-3.8-2.9-8.4V9.5c0-4.9,0-5.7,0-6.8c0-0.9,0.1-1.4-0.3-1.8C1.3,0.8,1.2,0.8,0.9,0.8S0,0.7,0,0.5%20C0.1,0.2,0.2,0.1,0.6,0.1'/%3e%3cpath%20class='st0'%20d='M31.3,21.2c-3.2-2.7-4-6.2-4-9.2c0-2.2,0.7-5.8,3.8-8.5c2.3-2.1,5.3-3.3,10.2-3.3c2,0,3.2,0.1,4.7,0.3%20c1.2,0.2,2.3,0.5,3.2,0.6c0.4,0,0.5,0.2,0.5,0.4c0,0.3-0.1,0.7-0.2,1.7c-0.1,1,0,2.7-0.1,3.4c0,0.5-0.1,0.8-0.4,0.8%20c-0.3,0-0.3-0.3-0.3-0.7c0-0.9-0.5-2.1-1.2-2.9c-1-1.1-2.7-1.8-5.6-1.8c-2.8,0-3.9,0.7-5.3,2c-2.3,2.1-3,5.1-3,8.1%20c0,7.4,5.8,11.2,10.1,11.2c2.9,0,3.1-0.1,4.4-1.5c0.6-0.6,0.9-1.9,1-2.4c0.1-0.5,0.2-0.7,0.5-0.7c0.2,0,0.3,0.2,0.3,0.5%20c0,0.4-0.4,3.1-0.8,4.1c-0.2,0.6-0.3,0.7-0.8,0.9c-1.3,0.5-3.8,0.8-5.8,0.8C37.9,24.6,34.2,23.6,31.3,21.2'/%3e%3cpath%20class='st0'%20d='M86,0.8c0.3-0.6,0.8-0.7,0.8-0.7c0.3,0,0.6,0.1,0.9,0.6l8.8,17.7l8.6-17.4c0.3-0.5,0.7-0.8,0.9-0.8%20c0.4,0,0.8,0.4,0.8,0.9l2.9,19.4c0.3,2,0.7,2.9,1.6,3.2c0.9,0.3,1.1,0.4,1.5,0.4c0.3,0,0.5,0,0.5,0.2c0,0.3-0.4,0.4-0.8,0.4%20c-0.8,0-5.3-0.1-6.6-0.2c-0.8-0.1-0.9-0.2-0.9-0.4s0.1-0.3,0.4-0.4c0.2-0.1,0.3-0.5,0.2-1.3l-2-13.8h0.1l-7,14.3%20c-0.8,1.5-1,1.7-1.5,1.7S94.4,24,94,23.1c-0.8-1.4-3.4-6.3-3.8-7.1c-0.3-0.7-2.3-4.6-3.4-6.9h0.4l-1.7,12.5%20c-0.1,0.6-0.1,0.9-0.1,1.5c0,0.6,0.5,0.8,0.9,1c0.6,0.1,1,0.2,1.3,0.2c0.3,0,0.5,0.1,0.5,0.2c0,0.3-0.3,0.4-0.8,0.4%20c-1.4,0-2.8-0.1-3.4-0.1c-0.7,0-2.2,0.1-3.2,0.1c-0.3,0-0.6-0.1-0.6-0.4c0-0.2,0.2-0.2,0.5-0.2s0.5,0,0.9-0.1%20c0.9-0.2,1-1.7,1.2-2.7L86,0.8z'/%3e%3cpath%20class='st0'%20d='M61.1,17.4c-0.3,0.1-0.9,0.3-1.3,0.9l-1.2,2.7C58.2,21.9,58,22.6,58,23c0,0.6,0.3,0.9,1.3,0.9h0.5%20c0.4,0,0.5,0.1,0.5,0.3c0,0.3-0.2,0.3-0.6,0.3c-1,0-2.4-0.1-3.5-0.1c-0.4,0-2.2,0.1-3.8,0.1c-0.5,0-0.7-0.1-0.7-0.3%20s0.1-0.3,0.4-0.3c0.3,0,0.8,0,1-0.1c1.5-0.2,2-1.6,2.6-3.2l8.2-19.7C64.2,0,65,0,65.1,0c0.3,0,0.6,0.2,1,1%20C67,2.7,72,15.6,74.2,20.4c1.2,2.8,2.2,3.3,2.8,3.4c0.5,0.1,0.6,0.1,0.9,0.1c0.3,0,0.5,0,0.5,0.3s-0.3,0.3-1.5,0.3%20c-1.1,0-3.6,0-6.1-0.1c-0.6,0-0.9,0-0.9-0.3c0-0.2,0.1-0.3,0.5-0.3c0.2-0.1,0.5-0.4,0.3-0.8l-2.2-4.8c-0.1-0.2-0.8-0.8-1.3-0.9%20C67.1,17.4,61.2,17.4,61.1,17.4%20M61.1,15.4c1.1,0.1,4.2,0.1,5.7,0c0.3,0,0.5-0.4,0.4-0.7l-2.7-7.8c-0.1-0.1-0.1-0.3-0.2-0.3%20c-0.1,0-0.2,0.2-0.2,0.3l-3.2,7.8C60.7,15,60.7,15.3,61.1,15.4'/%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e){kind=small}
Investigación Traslacional del Cáncer
Artículos JCR
Enrique González Billalabeitia, Vincenza Conteduca, Daniel Wetterskog, MTA Sharabiani, Enrique Grande, Maria Piedad Fernandez-Perez, Anu Jayaram, Samantha Salvi, Daniel Castellano, Alesandro Romanel, C Lolli, V Casadio, G Gurioli, D Amadori, Albert Font, Sergio Vazquez-Estevez, Arancha González del Alba, Begoña Mellado, Ovidio Fernández-Calvo, Maria Jose Méndez-Vidal, Miguel Angel Climent, Ignacio Duran, Enrique Gallardo, Alvaro Rodriguez, Carmen Santander, Maria Isabel Sáez, Javier Puente, D Gasi Tandafelt, Anna Wingate, D Dearnaley, Franchesca Demichelis, Enrique González-Billalabeitia, Gerhart Attard. 2017. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study. Revista: Annals of Oncology. Volumen 28. Páginas: 18051. Fuente de impacto: WOS_JCR. Índice de impacto: 11.8. Categoría: Desconocido. Posición/nº de revistas: 10/217.
Enrique González Billalabeitia, Enrique Gonzalez-Billalabeitia, Daniel Castellano, Nora Sobrevilla, Josep Guma, David Hervas, Maria I. Luengo, Jorge Aparicio, Alfonso Sanchez-Muñoz, Begoña Mellado, Alberto Saenz, Claudia Valverde, Antonio Fernandez, Mireia Margeli, Ignacio Duran, Sara Fernandez, Javier Sastre, Silverio Ros, Pablo Maroto, Ray Manneh, Pablo Cerezuela, Alberto Carmona-Bayonas, Francisco Ayala de la Peña, Jose Luis Aguilar, Samuel Rivera, Xavier García del Muro, Jose R. Germà-Lluch. 2017. Prognostic significance of venous thromboembolic events in disseminated germ-cell cancer patients. Revista: Journal of the National Cancer Institute. Volumen 109. Fuente de impacto: WOS_JCR. Índice de impacto: 12,589. Categoría: Oncology. Posición/nº de revistas: 9/217.
Enrique González Billalabeitia, A González del Alba, JA Arranz, J Puente, MJ Méndez-Vidal, E Gallardo, E Grande, B Pérez-Valderrama, E González-Billalabeitia, M Lázaro-Quintela, A Pinto, N Lainez, JM Piulats, E Esteban, JP Maroto-Rey, JA García, Cristina Suarez. 2017. Recent advances in genitourinary tumors: A review focused on biology and systemic treatment.. Revista: Critical Review Oncology Hematology. Volumen 113. Páginas: 1711. Fuente de impacto: WOS_JCR. Índice de impacto: 4,971. Categoría: Science Edition - ONCOLOGY. Posición/nº de revistas: 50/217.
Enrique González Billalabeitia, IK Vila, Y Yao, G Kim, W Xia, H Kim, SJ Kim, MK Park, JP Hwang, Enrique González-Billalabeitia, MC Hung, Su Jung Song, Min Sup Song. 2017. A UBE2O-AMPKα2 Axis that Promotes Tumor Initiation and Progression Offers Opportunities for Therapy. Revista: Cancer Cell. Volumen 31. Páginas: 2081. Fuente de impacto: WOS_JCR. Índice de impacto: 27.04. Categoría: Oncology. Posición/nº de revistas: 4/217.
Enrique González Billalabeitia, JL Pérez-Gracia, MF Sanmamed, A Bosch, A Patiño-García, KA Schalper, V Segura, J Bellmunt, J Tabernero, CJ Sweeney, TK Choureiri, M Martín, JP Fusco, ME Rodríguez-Ruiz, A Calvo, C Prior, Luis Paz-Ares, R Pio, Enrique González-Billalabeitia, A González-Hernández, D Paez, JM Piulats, A Gurpide, M Andueza, G de Velasco, R Pazo, Enrique Grande, P Nicolas, F Abad-Santos, J García-Donas, Daniel Castellano, MJ Pajares, Cristina Suarez, Ramón Colomer, LM Montuenga, Ignacio Melero. 2017. Strategies to design clinical studies to identify predictive biomarkers in cancer research. Revista: Cancer Treatment Reviews. Volumen 53. Páginas: 791. Fuente de impacto: WOS_JCR. Índice de impacto: 8.589. Categoría: Oncology. Posición/nº de revistas: 16/217.
Capítulos de libro
Enrique González Billalabeitia, Inmaculada Ballester. 2017. Perfil de seguridad. Papel de los niveles de imatinib en sangre. Editorial: Diego Marín. Páginas: 5011. Categoría: Desconocido.
Otros Artículos
Enrique González Billalabeitia, Beatriz Paumard-Hernández, O Calvete, L Inglada Pérez, H Tejero, F Al-Shahrour, G Pita, A Barroso, J Carlos Triviño, M Urioste, C Valverde, V Quiroga, J Francisco Rodríguez Moreno, A Fernández Aramburo, C López, P Maroto, J Sastre, M José Juan Fita, I Duran, I Lorenzo-Lorenzo, P Iranzo, X García Del Muro, S Ros, F Zambrana, A María Autran, J Benítez. 2018. Whole exome sequencing identifies PLEC, EXO5 and DNAH7 as novel susceptibility genes in testicular cancer. Revista: International Journal of Cancer. Volumen 143. Páginas: 19541. OTROS.Categoría: Desconocido.
Enrique González Billalabeitia, Jorge Aparicio, Alfonso Sanchez-Muñoz, Josep Guma, Montse Domenech, JA Meana, J García-Sanchez, R Bastus, Regina Girones, Enrique Gonzalez-Billalabeitia, N Sagastibelza, S Ochenduszko, A Sanchez, Josefa Terrasa, Josep Ramon Germa-Lluch, Xavier García del Muro. 2018. A Risk-Adapted Approach to Patients with Stage I Seminoma according to the Status of Rete Testis: The Fourth Spanish Germ Cell Cancer Group Study. Revista: Oncology. Volumen 95. Páginas: 81. OTROS.Categoría: Desconocido.
Proyectos competitivos
SOG-MIE-2014-04. Estudio fase II multicéntrico y observacional que analiza el valor predictivo de respuesta a enzalutamida del gen de fusión TMPRSS2-ETS en pacientes con CPRC metastásico no tratados previamente con quimioterapia. Enrique Grande(IP). Grupo Español de Tumores Urologicos (SOGUG). (2015-2017). Cuantía total: 235.000,00€.
Estudio co-clínico en el cancer de próstata. Enrique González Billalabeitia(IP). Instituto de salud carlos III (. (2010-2012).
Proyectos no competitivos